Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: DCTH

Delcath Systems, Inc.

Healthcare | Medical - Devices

No licensed closing price on file for DCTH. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$0.01

Delcath Systems, Inc. (NASDAQ: DCTH) is a medical device company. Figures from SEC EDGAR; updated 2026-10-21 11:09 UTC.

What Delcath Systems, Inc. does

Delcath Systems is an interventional oncology company that develops treatments for cancers affecting the liver, whether originating there or spreading to it from elsewhere. The company's primary product, HEPZATO KIT, combining the drug melphalan with a hepatic delivery system, received FDA approval in August 2023 for treating uveal melanoma that has metastasized to the liver, with first commercial use beginning in January 2024.

Summarized from Delcath Systems, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$0.01
Return on equity2.43%

Revenue, margins & earnings

FY2021: net loss $26M on revenue $4M$4MFY2021FY2022: net loss $37M on revenue $3M$3MFY2022FY2023: net loss $48M on revenue $2M$2MFY2023FY2024: net loss $26M on revenue $37M$37MFY2024FY2025 Revenue: $85M — margin split not shown (non-operating gains)$85MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-14
  • 2026-10-14DirectorConversion3,627—
  • 2026-10-14DirectorOther-27,502—
  • 2026-10-14DirectorSeries E preferredConversion-36—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Delcath Systems, Inc. do?

Delcath Systems is an interventional oncology company that develops treatments for cancers affecting the liver, whether originating there or spreading to it from elsewhere.

When did DCTH last file with the SEC?

Delcath Systems, Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-14. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 11:09 UTC. This page is also available as JSON at /api/data?ticker=DCTH and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for DCTH and 5,000+ tickers.

Create a free account — keep DCTH
For your agent
GET /api/data?ticker=DCTH

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt